Chevron (NYSE: CVX) CFO exercises options and sells 45,800 shares
Rhea-AI Filing Summary
Chevron Corporation’s Chief Financial Officer Eimear P. Bonner reported a series of option exercises and related share sales. She exercised non-qualified stock options into 45,800 shares of common stock on February 27 and March 2, 2026, then sold 45,800 shares in open-market transactions.
The sales, at weighted-average prices generally in the mid-$180s to about $190.60 per share, were carried out under a Rule 10b5-1 trading plan adopted on November 22, 2025. After these transactions, she directly owned 8,427 Chevron shares and indirectly held 408 shares through a share incentive plan.
Positive
- None.
Negative
- None.
Insights
Chevron’s CFO exercised options and sold an offsetting number of shares under a pre-set plan.
Chevron’s Chief Financial Officer, Eimear P. Bonner, exercised non-qualified stock options to acquire 45,800 shares of common stock, then sold 45,800 shares in open-market trades. These transactions used code M for derivative exercises and S for sales, reflecting both option conversion and share disposals.
The filing notes that all reported sales followed a Rule 10b5-1 trading plan adopted on November 22, 2025, meaning trades were pre-arranged when she did not yet know future market conditions. Reported sale prices cluster in ranges around $184–$191 per share, with weighted-average prices disclosed for each block.
After these trades, Bonner directly held 8,427 Chevron shares and had 408 shares held indirectly through a share incentive plan. The net effect is a net-sell of 45,800 shares, but the use of a 10b5-1 plan and the modest size relative to Chevron’s overall equity base point to a routine executive liquidity and compensation event.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 17,400 | $0.00 | -- |
| Exercise | Common Stock | 17,400 | $179.08 | $3.12M |
| Sale | Common Stock | 17,400 | $190.60 | $3.32M |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 18,800 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 9,600 | $0.00 | -- |
| Exercise | Common Stock | 18,800 | $152.35 | $2.86M |
| Exercise | Common Stock | 9,600 | $153.22 | $1.47M |
| Sale | Common Stock | 5,500 | $184.2776 | $1.01M |
| Sale | Common Stock | 2,500 | $185.3335 | $463K |
| Sale | Common Stock | 18,100 | $186.5605 | $3.38M |
| Sale | Common Stock | 2,300 | $187.1605 | $430K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2025. This number includes rounding of fractional shares. This transaction was executed in multiple trades at prices ranging from $183.85 to $184.82, inclusive. The price reported in Column 4 reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form. These shares were sold in multiple transactions at prices ranging from $184.85 to $185.83, inclusive. The price reported in Column 4 reflects the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $185.87 to $186.85, inclusive. The price reported in Column 4 reflects the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $186.95 to $187.43, inclusive. The price reported in Column 4 reflects the weighted average sale price. Option granted 2/6/2024. One-third of the shares subject to the option vested on February 10, 2025 and February 10, 2026, respectively, and one-third of the shares will vest on February 10, 2027. Option granted 2/4/2025. One-third of the shares subject to the option vested on February 10, 2026 and one-third of the shares will vest on February 10, 2027 and February 10, 2028, respectively. Option granted 1/25/2023. One-third of the shares subject to the option vested on January 31, 2024, January 31, 2025 and January 31, 2026, respectively.
